000095077 001__ 95077
000095077 005__ 20210902121747.0
000095077 0247_ $$2doi$$a10.3390/jcm9051526
000095077 0248_ $$2sideral$$a118738
000095077 037__ $$aART-2020-118738
000095077 041__ $$aeng
000095077 100__ $$aLaredo, Viviana
000095077 245__ $$aNo differences in gastrointestinal bleeding risk among clopidogrel-, ticagrelor-, or prasugrel-based dual antiplatelet therapy
000095077 260__ $$c2020
000095077 5060_ $$aAccess copy available to the general public$$fUnrestricted
000095077 5203_ $$aThe risk for gastrointestinal bleeding from dual antiplatelet therapy (DAPT) with new antiplatelets (prasugrel/ticagrelor) compared to clopidogrel is unclear. Aim: To determine the risk and type of major (gastrointestinal bleeding requiring hospitalization) and minor (anemia and iron deficiency) gastrointestinal events with different types of DAPT. Methods: Retrospective observational cohort study of patients who started DAPT after percutaneous coronary intervention. Follow-up was censored after 12 months of DAPT, when a major gastrointestinal event occurred, or when DAPT was discontinued. Results: Among 1, 327 patients (54.03% were treated with clopidogrel-based DAPT, 38.13% with ticagrelor-based DAPT, and 7.84% with prasugrel-based DAPT), 29.5% had at least one gastrointestinal event. Patients taking clopidogrel-DAPT were older, with more comorbidities, and higher gastrointestinal risk compared to those taking other DAPT regimens. Adjusted hazard ratios (HRs) showed no between-group differences in the risk for major (clopidogrel vs. new antiplatelets: HR 0.996; 95% confidence interval 0.497-1.996) and minor (HR 0.920; 0.712-1.189) gastrointestinal events. Most patients received proton pump inhibitors while on DAPT (93.3%) and after withdrawal (83.2%). Conclusion: Prasugrel- or ticagrelor-based DAPT was not associated with increased gastrointestinal bleeding risk when compared to clopidogrel-DAPT. New antiplatelets do not necessarily need to be restricted to patients with low gastrointestinal risk.
000095077 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000095077 590__ $$a4.241$$b2020
000095077 591__ $$aMEDICINE, GENERAL & INTERNAL$$b39 / 169 = 0.231$$c2020$$dQ1$$eT1
000095077 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000095077 700__ $$0(orcid)0000-0001-7466-3876$$aSostres, Carlos$$uUniversidad de Zaragoza
000095077 700__ $$aGarcia, Sandra
000095077 700__ $$aCarrera-Lasfuentes, Patricia
000095077 700__ $$aRevilla-Marti, Pablo
000095077 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, Ángel$$uUniversidad de Zaragoza
000095077 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000095077 773__ $$g9, 5 (2020), 1526 [10 pp.]$$pJ. clin.med.$$tJOURNAL OF CLINICAL MEDICINE$$x2077-0383
000095077 8564_ $$s641824$$uhttps://zaguan.unizar.es/record/95077/files/texto_completo.pdf$$yVersión publicada
000095077 8564_ $$s480456$$uhttps://zaguan.unizar.es/record/95077/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000095077 909CO $$ooai:zaguan.unizar.es:95077$$particulos$$pdriver
000095077 951__ $$a2021-09-02-09:47:05
000095077 980__ $$aARTICLE